



Announcement Summary

Entity name

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD

Announcement Type

New announcement

Date of this announcement

Wednesday November 11, 2020

The Proposed issue is:

☒ A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
n/a	Lead manager options, with exercise price of \$0.45 and expiry two years from date of issue	1,600,000
NSB	ORDINARY FULLY PAID	8,571,429

Proposed +issue date

Friday November 13, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

13102832995

1.3 ASX issuer code

NSB

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

Wednesday November 11, 2020

1.6 The Proposed issue is:

☒ A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☒ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

☒ Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ASX +security code and description

NSB : ORDINARY FULLY PAID

Number of +securities proposed to be issued

8,571,429

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

☒ Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.28000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes



Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

☒ New class

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

☒ Yes

Will the entity be seeking quotation of the 'new' class of +securities on ASX?

☒ No

ASX +security code

New class-code to be confirmed

+Security description

Lead manager options, with exercise price of \$0.45 and expiry two years from date of issue

+Security type

Options

Number of +securities proposed to be issued

1,600,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

☒ Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.00001

Will all the +securities issued in this class rank equally in all respects from their issue date?

☒ Yes

Options details

**+Security currency**

AUD - Australian Dollar

Exercise price

AUD 0.4500

Expiry date

Friday November 11, 2022

Details of the type of +security that will be issued if the option is exercised

NSB : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One fully paid ordinary shares (ASX:NSB)

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Please see the Company's announcement to the market dated 11 November for material terms.

Part 7C - Timetable**7C.1 Proposed +issue date**

Friday November 13, 2020

Part 7D - Listing Rule requirements**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?**

☒ Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

Friday November 29, 2019

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

☒ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

☒ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

☒ No

Part 7E - Fees and expenses**7E.1 Will there be a lead manager or broker to the proposed issue?**

☒ Yes



7E.1a Who is the lead manager/broker?

Westar Capital Ltd

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Fees payable in cash by the company to the Lead Manager in connection with the Offering will consist of a selling fee of 6% of the aggregate gross proceeds. Additionally, the Lead manager will be issued 1,600,000 options ("Lead Manager options"), with strike price of \$0.45 and expiry date two years from issue.

7E.2 Is the proposed issue to be underwritten?

☒ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

A fee payable in cash by the company of \$50,000 to the non-executive Chair on completion of a successful capital raise, as per contractual agreement.

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Additional working capital in order to accelerate the Company's research and development pipeline.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

☒ No

7F.2 Any other information the entity wishes to provide about the proposed issue

Please refer to the Company's announcement to the market dated 11 November 2020 for additional information.